Back to Authors

Patnaik, Mrinal M.

https://orcid.org/0000-0001-6998-662X

Mayo Clinic

Mayo Clinic

Citations 648

Venetoclax plus hypomethylating agents in DDX41‐mutated acute myeloid leukaemia and myelodysplastic syndrome: Mayo Clinic series on 12 patients
Nanaa, Ahmad , He, Rong , Foran, James M. , Badar, Talha , Gangat, Naseema , Pardanani, Animesh , Litzow, Mark R. , Patnaik, Mrinal M. , Al‐Kali, Aref , Al-Kali, Aref , Alkhateeb, Hassan B , Nanaa, Ahmad , Badar, Talha , Hogan, William J. , Alkhateeb, Hassan B.

British Journal of Haematology | September 15, 2023 | Volume: 204 | Issue: 1 | Pages: 171-176

10.1111/bjh.19105 Get It

SummaryVenetoclax (VEN) is an FDA‐approved selective inhibitor of B‐cell leukaemia/lymphoma‐2 (BCL‐2), used for treating elderly or unfit acute myeloid leukaemia (AML) patients unable to undergo intensive chemotherapy. Combining VEN with hypomethylating agents (HMAs) has shown impressive response rates in high‐risk myelodysplastic syndromes (MDS) and relapsed/refractory AML. However, the efficacy of VEN and HMAs in treating DDX41‐mutated (mDDX41) MDS/AML patients remains uncertain. Despite the favourable prognostic nature of mDDX41 MDS/AML patients, there is a lack of clinical experience regarding their response to different treatment regimens, leading to an unknown optimal therapeutic approach.
Germline DDX41 mutant predisposition syndromes: Slow driver states to hematological malignancies
Chlon, Timothy M. , Patnaik, Mrinal M. , Chlon, Timothy M.

American Journal of Hematology | September 14, 2023 | Volume: 98 | Issue: 11 | Pages: 1673-1676

10.1002/ajh.27091 Get It

Reappraisal of mast cell leukemia based on a single institution review of 16 cases: Mast cell morphology determines clinical outcome
Pardanani, Animesh , Tefferi, Ayalew , Al‐Kali, Aref , Patnaik, Mrinal M. , Begna, Kebede H. , Elliott, Michelle A. , Khera, Nandita , Palmer, Jeanne , Gangat, Naseema , Kelemen, Katalin, Reichard, Kaaren K. , Patnaik, Mrinal , Begna, Kebede , Elliott, Michelle , Gangat, Naseema , Orazi, Attilio , Chen, Dong , Hogan, William J. , Orazi, Attilio , Chen, Dong

American Journal of Hematology | September 9, 2023 | Volume: 99 | Issue: 1 | Pages: No page available

10.1002/ajh.27089 Get It

P709: H2AK119UB IN THE TRANSCRIPTIONAL REGULATION OF PATIENTS WITH ASXL1-MUTANT CHRONIC MYELOMONOCYTIC LEUKEMIA
Lasho, Terra, Finke, Christy M. , Mangaonkar, Abhishek A. , Patnaik, Mrinal M. , Binder, Moritz , Wang, Liguo , Safgren, Stephanie L. , Lee, Jeong‐Heon , Fernandez, Jenna , Gaspar‐Maia, Alexandre

HemaSphere | August 22, 2023 | Volume: 7 | Issue: S3 | Pages: e5593144

10.1097/01.hs9.0000969740.55931.44 Get It

P580: CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH WT1 MUTATED MYELOID NEOPLASMS: MAYO CLINIC EXPERIENCE
Basmaci, Rami, He, Rong , Viswanatha, David S., Foran, James M. , Mangaonkar, Abhishek A. , Litzow, Mark R. , Benga, Kebede, Gangat, Naseema , Tefferi, Ayalew , Patnaik, Mrinal M. , Al‐Kali, Aref , Baranwal, Anmol , Greipp, Patricia T. , Yi, Cecilia Arana , Shah, Meera , Hogan, William J. , Saliba, Antoine N. , Alkhateeb, Hassan B.

HemaSphere | August 22, 2023 | Volume: 7 | Issue: S3 | Pages: e84724f8

10.1097/01.hs9.0000969224.84724.f8 Get It

S263: CYTOPENIAS, AGE AND CAR-HEMATOTOX SCORE PREDICT THE DEVELOPMENT OF POST CAR T-CELL THERAPY-RELATED MYELOID NEOPLASMS
Shah, Syed , Bansal, Radhika , Hathcock, Matthew , Kharfan‐Dabaja, Mohamed A. , Kourelis, Taxiarchis , Patnaik, Mrinal M. , Al‐Kali, Aref , Gurney, Mark E. , Alkhateeb, Hassan B. , Rosenthal, Allison , Chen, Dong , Kenderian, Saad S. , Lin, Yi , Shah, Meera

HemaSphere | August 10, 2023 | Volume: 7 | Issue: S3 | Pages: e6718317

10.1097/01.hs9.0000967964.67183.17 Get It